Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast mri after neoadjuvant chemotherapy

Annals of Surgery

Volumn 257, Issue 1, 2013, Pages 133-137

  Moon, Hyeong Gon ^a   Han, Wonshik ^a,b   Ahn, Soo Kyung ^a   Cho, Nariya ^c   Moon, Woo Kyung ^c   Im, Seock Ah ^b,c   Park, In Ae ^d   Noh, Dong Young ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Department of Radiology ^*  (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Breast cancer; estrogen receptor; HER2 gene; magnetic resonance imaging; neoadjuvant; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PERTUZUMAB; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PHENOTYPE; PREOPERATIVE CARE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84871622189     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182686bd9     Document Type: Article

References (25)

1. Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breastcancer. Br J Surg. 2005;92:14-23.
2. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment ofoperable breast cancer: an update. J Clin Oncol. 2006;24:1940-1949. (Pubitemid 46638994)
3. Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008;26:791-797. (Pubitemid 351265334)
4. Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg. 1995;222:612-618.
5. Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy ofphysical examina-tion, ultrasonography and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy Ann Surg. 2006;243:257-264. (Pubitemid 43185446)
6. Le-Petross HC, Hylton N. Role of breast MR imaging in neoadjuvant chemotherapy Magn Reson Imaging Clin N Am. 2010;18:249-258, viii-ix.
7. Moon HG, Han W, Lee JW, et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol. 2009;20:636-641.
8. Nakahara H, Yasuda Y, Machida E, et al. MRand USimagingforbreastcancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison oftriple negative breast cancer and other intrinsic subtypes. Breast Cancer. 2011;18:152-160.
9. Straver ME, Loo CE, Rutgers EJ, et al. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg. 2010;251:701-707.
10. Moon HG, Han W, Noh DY. Comparable survival between p N0 breast cancer patients undergoing sentinel node biopsy and extensive axillary dissection: a report from the Korean Breast Cancer Society. J Clin Oncol. 2010;28:1692-1699.
11. Choi HK, Cho N, Moon WK, et al. Magnetic resonance imaging evaluation of residual ductal carcinoma in situ following preoperative chemotherapy in breastcancerpatients. Eur J Radiol. 2012;81:737-743.
12. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814-819. (Pubitemid 351265335)
13. Carey LA, Dees EC, Sawyer L, et al. The triplenegative paradox: primary tumor chemosensitivityofbreastcancer subtypes. Clin Cancer Res. 2007;13:2329-2334. (Pubitemid 46698581)
14. Chen JH, Mehta RS, Carpenter PM, et al. Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvantchemotherapy. J Clin Oncol. 2007;25:5667-5669.
15. Li SP, Padhani AR, Taylor NJ, et al. Vascular characterisation of triple negative breast carcinomasusing dynamic MRI.Eur Radiol. 2011;21:1364-1373.
16. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dy-namic contrast-enhanced magnetic resonance imaging. JMagn Reson Imaging. 2003;17:509-520. (Pubitemid 36528666)
17. Klos KS, Wyszomierski SL, Sun M, et al. Erb B2 increases vascular endothe-lial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metas-tasis ofhumanbreastcancer cells. Cancer Res. 2006;66:2028-2037.
18. Blackwell KL, Dewhirst MW, Liotcheva V, et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res. 2004;10:4083-4088. (Pubitemid 38812486)
19. Kos KS, Zhou XY, Lee S, et al. Combined trastuzumab and paclitaxel treatment better inhibits Erb B-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer. 2003;98:1377-1385. (Pubitemid 37151491)
20. Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-280. (Pubitemid 34260234)
21. Chen JH, Feig B, Agrawal G, et al. MRI evaluation ofpathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112:17-26.
22. Mathews MS, Linskey ME, Hasso AN, et al. The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg Neurol. 2008;70:649-652; discussion 653.
23. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the Gepar Quattro study. J Clin Oncol. 2010;28:2024-2031.
24. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemother-apy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377-384.
25. Gianni L, Pienkowski T, Im YH, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (Neosphere). Cancer Res. 2010;70:82s.